Enrollment completed in Phase III Copaxone MS trial
Enrollment completed in Phase III Copaxone MS trial
Teva Pharmaceutical Industries Ltd. today announced completion of patient enrollment for the GALA (Glatiramer Acetate Low-frequency Administration) trial. This international Phase III trial in patients with relapsing-remitting multiple sclerosis (RRMS), is designed to examine the efficacy, safe... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post